University of South Florida

Digital Commons @ University of South Florida
Chemistry Faculty Publications

Chemistry

2018

Distinct Mechanisms of Alterations in DNA Methylation/
Demethylation Leading to Myelodysplastic Syndromes/Acute
Myeloid Leukemia and Chronic Lymphocytic Leukemia
Cristina Bagacean
University of Brest

Anne Bordron
University of Brest

Tempescul Adrian
University of Brest

Jean Christophe Ianotto
University of Brest

Gaelle Guillerm
University of Brest

See next page for additional authors
Follow this and additional works at: https://digitalcommons.usf.edu/chm_facpub

Scholar Commons Citation
Bagacean, Cristina; Bordron, Anne; Adrian, Tempescul; Ianotto, Jean Christophe; Guillerm, Gaelle; Brooks,
Wesley; Couturier, Marie-Anne; Zdrenghea, Mihnea; Berthou, Christian; and Renaudineau, Yves, "Distinct
Mechanisms of Alterations in DNA Methylation/Demethylation Leading to Myelodysplastic Syndromes/
Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia" (2018). Chemistry Faculty Publications.
134.
https://digitalcommons.usf.edu/chm_facpub/134

This Article is brought to you for free and open access by the Chemistry at Digital Commons @ University of South
Florida. It has been accepted for inclusion in Chemistry Faculty Publications by an authorized administrator of
Digital Commons @ University of South Florida. For more information, please contact scholarcommons@usf.edu.

Authors
Cristina Bagacean, Anne Bordron, Tempescul Adrian, Jean Christophe Ianotto, Gaelle Guillerm, Wesley
Brooks, Marie-Anne Couturier, Mihnea Zdrenghea, Christian Berthou, and Yves Renaudineau

This article is available at Digital Commons @ University of South Florida: https://digitalcommons.usf.edu/
chm_facpub/134

Open Access

OBM Genetics

Review

Distinct Mechanisms of Alterations in DNA Methylation/Demethylation
Leading to Myelodysplastic Syndromes/Acute Myeloid Leukemia and
Chronic Lymphocytic Leukemia
Cristina Bagacean 1, 2, 3, Anne Bordron 3, Tempescul Adrian 1, 3, Jean Christophe Ianotto 3, Gaelle
Guillerm 3, Wesley H Brooks 4, Marie-Anne Couturier 3, Mihnea Zdrenghea 5, Christian Berthou 1, 3,
Yves Renaudineau 2, 3, *
1. Department of Clinical Hematology, CHU Morvan, Brest, France; E-Mails:
cristina.bagacean@univ-brest.fr; Adrian.tempescul@chu-brest.fr; cberthou@univ-brest.fr;
jean.christophe.ianotto@chu-brest.fr;
gaelle.guillerm@chu-brest.fr;
marieanne.couturier@chu-brest.fr
2. Laboratory of Immunology and Immunotherapy, CHU Morvan, Brest, France; E-Mails:
cristina.bagacean@univ-brest.fr; yves.renaudineau@univ-brest.fr
3. INSERMU1127, B lymphocyte and autoimmunity, INSERM, University of Brest, REpiCGO,
ICCGO, Brest, France; E-Mails: cristina.bagacean@univ-brest.fr; anne.bordron@univ-brest.fr;
Adrian.tempescul@chu-brest.fr; cberthou@univ-brest.fr; yves.renaudineau@univ-brest.fr
4. Department of Chemistry, University of South Florida, Tampa, USA; E-Mail:
wesleybrooks@usf.edu
5. Department of Hematology, "Prof. Dr. Ion Chiricuta" Oncology Institute, Cluj-Napoca, Romania;
E-Mail: mzdrenghea@umfcluj.ro
* Correspondence: Yves Renaudineau; E-Mail: yves.renaudineau@univ-brest.fr
Academic Editors: Marcel Mannens and Stéphane Viville
Special Issue: Epigenetic Mechanisms in Health and Disease
OBM Genetics
2018, volume 2, issue 4
doi:10.21926/obm.genet.1804054

Received: June 05, 2018
Accepted: November 28, 2018
Published: December 14, 2018

Abstract:
Epigenetic dysregulation is present in both myeloid and lymphoid disorders, with important
differences reported between myelodysplastic syndromes (MDS)/acute myeloid leukemia
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conditions of the Creative Commons by Attribution License, which permits
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(AML), on one hand, and chronic lymphocytic leukemia (CLL), on the other. Qualitative
differences are reported in MDS/AML with gene fusions (e.g. TET1/LCX) and somatic
mutations in epigenetic regulators (e.g. DNMT3A, TET2, IDH1/2), while differences in CLL are
predominantly quantitative (e.g. DNMT3A, TET2). Indeed, and as supported by studies in
animal models, a defective DNA methylation/demethylation process represents a
competitive advantage to the myeloid lineage and an early event in MDS/AML, while in the
case of CLL, epigenetic events appear later and are associated with disease progression.
Finally, in both MDS/AML and CLL, the focal or global DNA methylation/demethylation
process is altered and contributes to disease progression and activity. In conclusion, a better
understanding of the epigenetic regulators involved in myeloid/lymphoid differentiation,
their localization and the co-recruitment of other proteins at specific DNA target sites, could
offer us the possibility to modulate hematopoiesis, and control disease initiation and/or
progression.
Keywords
DNA methylation; DNA hydroxymethylation; MDS; AML; CLL; TETs; DNMTs

1. Introduction
Myelodysplastic syndromes (MDS) comprise a diverse group of clonal and malignant myeloid
disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and an increased risk
of progression to acute myeloid leukemia (AML), either gradually or rapidly [1]. AML is the most
frequently occurring acute leukemia in adults, with malignant transformation occurring in
primitive hematopoietic stem and progenitor cells, leading to increased proliferation and impaired
differentiation [2, 3]. A wide heterogeneity of genetic mutations has been identified in both MDS
and AML, the most frequent involving epigenetic processes, including the control of DNA
methylation, RNA splicing, histone modifications, transcription factor function, DNA repair, and
kinase signaling.
Another hematologic pathology presenting important epigenetic modifications, is chronic
lymphocytic leukemia (CLL), which is the most common type of leukemia, with a median age at
diagnosis ranging from 67 to 72 years [4, 5]. CLL is characterized by the clonal proliferation and
accumulation of mature, long-lived CD5+ B cells in peripheral blood, bone marrow, lymph nodes
and secondary lymphoid organs [6]. Several hypotheses have been formulated regarding the cell
of origin for CLL B cells. Initially, based on the subdivision of CLL patients into two main subgroups
according to their immunoglobulin heavy chain variable region (IGHV) mutational status, it was
suspected that CLL cells were derived either from naïve B cells, in the case of the IGHV unmutated
(UM) CLL B cells, or from memory B cells, in the case of mutated (M) CLL B cells. Subsequently, this
dichotomy lost support with the development of gene expression microarray analysis, which is
considered to be the gold standard technique for classifying the different lymphoid malignancies
based on their cell of origin. Indeed, according to Klein et al. and validated since, transcriptome
analysis revealed only a small number of differences between IGHV-UM and IGHV-M CLL B cells,
supporting the possibility that both subsets are related to memory B cells [7]. A recent study has
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confirmed these findings by integrating DNA methylation data and comparing normal B cell
subsets to malignant B cells from 268 patients with CLL. This analysis showed that CLLs are derived
largely from a continuum of memory B cell maturation states ranging from low- to high-maturity
[8] In addition, such analysis verified the observation that the CLL methylation status resembles
the that of memory B cells, accounting for 70%–100% of the programming for high-maturity
memory B cells. However, the debate is not closed regarding the origin of CLL cells, and there is
mounting evidence supporting the occurrence of the primary oncogenic event not at the memory
B cell stage, but earlier in the HSC counterpart, and that the leukemogenic transformation is a
step-wise process involving the accumulation of oncogenic events during B cell differentiation to
the memory B cell stage [9]. In MDS/AML, somatic mutations are presented in epigenetic
regulators. In contrast, in CLL, epigenetic modifications are not qualitative, but mainly quantitative
and affect the expression of epigenetic sensitive genes, such as CD5 and CD20, with differences
reported during CLL disease progression [10-12]. Such a dichotomy may explain the absence of the
simultaneous occurrence of CLL and MDS/AML, except in CLL patients receiving chemotherapeutic
and mutagenic agents.
Accordingly, the aim of this review is to discuss the parallels between MDS/AML and CLL,
diseases that represent two different mechanisms by which the epigenetic landscape is modified:
by somatic mutations (qualitative) in MDS/AML, and at the expression level (quantitative) in CLL.
Concerning MDS/AML, epigenetic dysregulation is an early event, conferring a competitive
advantage on the myeloid lineage and leading to self-renewal. On the other hand, in CLL, there is a
step-wise process in which methylation dysregulation represents a secondary event and
contributes to disease progression.
2. DNA Methylation and Demethylation
DNA methylation occurs predominantly at position 5 of the cytosine and represents the most
studied epigenetic marker. Research on this cytosine methylation in cancer began in the 1970s
when analysis of tumors revealed significant aberrations in 5-methylcytosine (5-mCyt).
Furthermore, in 2009, rapid breakthroughs came with the characterization of an active DNA
demethylation enzymatic process that starts with the conversion of 5-mCyt to 5-hydroxy(h)mCyt
(Figure 1) [13, 14].
Currently, due to important advances in DNA methylation analysis technologies, whole-genome
scale methylation maps are available for several human cell types and show that the methylation
is mainly restricted to cytosine-phospho-guanosine (CpG) sites. The human genome contains
approximately 29 million CpG sites, 60% to 80% of which are generally methylated and with
important differences among cell types [15]. Compartment-specific analysis of the methylome
showed that DNA methylation has an important role in maintaining the latent transcriptional
repression of pericentromeric repeats and transposable repetitive elements [16-19]. This is
essential for genomic stability and normal mitosis, by controlling chromosome alignment,
segregation and integrity. The human genome is globally methylated with the exception of a small
fraction (1%–2%) of the total genome which possesses CpG rich spots, referred to as CpG islands.
These regions are predominantly located in transcriptionally active gene areas and are usually
close to the first exon of a gene. The asymmetric distribution of DNA methylation between cell
types has been shown to have functional implications in the epigenetic guidance of development,

Page 3/21

OBM Genetics 2018; 2(4), doi:10.21926/obm.genet.1804054

cellular differentiation and more recently, in nuclear organization; however, our understanding of
this distribution and its effects is still incomplete [20-23]. Approximately 70% of gene promoters
overlap with CpG islands and it is generally accepted that the state of CpG methylation in these
DNA regions, regulates gene expression through modification of chromatin structure and
accessibility to the transcription machinery [24, 25]. The methylation process is catalyzed by the
DNA methyltransferase (DNMT) enzymes, including DNMT1, DNMT3A, and DNMT3B, with the help
of accessory proteins, such as DNMT3L and UHRF1.

Figure 1 Pathways of cytosine methylation and demethylation mediated by DNA
methyltransferase (DNMT) and ten-eleven translocation (TET) proteins.
(Note: In MDS/AML, the main DNA methylation/demethylation regulators are DNMT1
(overexpressed), DNMT3A and TET2, presenting loss of function due to mutations, and
IDH1/2 that repress TET2 through α-KG inhibition when mutated. In CLL, DNMT3A and
TET2 expression is altered during disease progression. Cyt: cytosine; 5-mCyt: 5methylcytosine; 5-hmCyt: 5-hydroxymethylcytosine; α-KG: α-ketoglutarate; 2-HG: 2hydroxy-glutarate; IDH1/2: isocitrate dehydrogenase. MDS: myelodysplastic syndrome;
AML: acute myeloid leukemia; CLL: chronic lymphocytic leukemia.)
DNMTs catalyze the transfer of a methyl group from the methyl donor S-adenosyl-L-methionine
(SAM), to position 5 of cytosine residues in DNA [26]. SAM, in turn, is consumed by increased
activation of the polyamine synthesis and recycling pathways [27]. The first DNMT to be purified
was shown to have a preferential affinity for hemi-methylated DNA substrates, and therefore is
considered responsible for maintaining the methylation pattern during DNA replication [28]. The
gene encoding this enzyme was subsequently cloned and sequenced by the same group and
named DNMT1 [29].
The observation that DNA methylation is not completely lost after DNMT1 inactivation
suggested that cells must contain a de novo methylation activity. Later, Li and colleagues identified
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and cloned two novel methyltransferases [30]. These genes are expressed as two proteins,
DNMT3A and DNMT3B, with similar structure and domain organization. These enzymes do not
differentiate between hemi-methylated and unmethylated CpG sites and are responsible for de
novo DNA methylation, in association with DNMT3L, which has a regulatory function and no
methylation capacity per se [31].
Regarding the active DNA demethylation process, 5-hmCyt was identified shortly after the
discovery of 5-mCyt [32]. After this discovery, no remarkable research was published on the
subject, until the ten-eleven translocation (TET)1 protein was discovered and shown to be capable
of erasing methylation marks via oxidation to 5-hmCyt [14]. By definition, active DNA
demethylation refers to the enzymatic process by which 5-mCyt and demethylation intermediates
are replaced by an unmodified cytosine in a replication-independent manner [33]. In contrast, the
failure to maintain DNA methylation marks across cell divisions, resulting in the dilution of 5-mCyt
during replication, is referred to as passive DNA demethylation. TET1 belongs to a family of
enzymes which also includes TET2 and TET3 and catalyze the successive transformation of 5-mCyt
to 5-hmCyt, 5-formylcytosine (5-fCyt) and 5-carboxylcytosine (5-CaCyt) in a Fe(II)- and 2oxoglutarate-dependent manner [34, 35].
Methylation genome mapping provided important insights into the role of 5-mCyt. Similarly,
genome mapping of the demethylation process intermediates, and in particular 5-hmCyt, have
been shown to be associated with important epigenetic regulatory functions. Indeed, 5-hmCyt
content is highly variable in normal human tissues and higher levels of 5-hmCyt content are found
in areas of transcriptional control, including promoters, transcription factor binding sites and gene
bodies [36]. However, as highlighted in a recently published study, the relationship between 5hmCyt peaks and gene transcription is complex, which raises important questions and challenges
based on some of the data provided so far by DNA methylome analysis using microarrays or the
reduced representation bisulfite sequencing (RRBS) techniques [37]. In this study, Zhang et al.
demonstrated that the 5-mCyt distribution is only poorly correlated with gene expression,
whereas the 5-hmCyt displays a “bi-modal” pattern in HSC with a high 5-hmCyt distribution in the
promoter and gene body associated with highly expressed genes, while high 5-hmCyt levels in the
transcription start sites (TSS) reveal lower relative gene expression [37]. The positive association
between high 5-hmCyt content in the gene bodies with gene expression in embryonic HSC was
also demonstrated in a study by Huang et al. which, additionally, demonstrated a correlation with
TET2 activity [38].
Another interesting observation concerning the mechanisms by which the fragile balance
between methylation and hydroxymethylation is adjusted is that DNMT3A and TET1 function in a
complementary and competitive manner, as demonstrated by Gu et al [39]. This study showed
that normal epigenetic landscapes and gene expression are maintained by TET1, which limits DNA
methylation partially by protecting the cytosine target from DNMT3A and establishing boundaries
for DNA methylation.
Methylation and demethylation enzymes have also been shown to contribute to the
adjustment of the epigenetic landscape and transcriptional regulation in an enzyme-independent
manner, by simply recruiting other enzymes and co-factors. For example, there is a direct
interaction of TET2 and TET3 with O‐GlcNAc transferase (OGT) [40]. TET2/3–OGT co‐localizes on
chromatin at active promoters enriched for H3K4me3 and reduction of either TET2/3 or OGT
activity results in a direct decrease in H3K4me3 and concomitantly decreased transcription.
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Independent of its catalytic activity, TET1 also has a role in transcriptional repression through its
interaction with the SIN3A complex [41]. These interactions complicate the interpretation of the
link between the localization on the genome of methylation/hydroxymethylation enzymes,
methylated/ hydroxymethylated CpGs and transcriptional regulation.
3. Knowledge Gained from Mouse Models: The Link between DNA Methylation, Myeloid or the
Lymphoid Lineage Commitment, Self-Renewal and Differentiation
The hematopoietic system and its hierarchical cascade of differentiation provides
comprehensive information on the DNA methylation/demethylation process during differentiation
(Figure 2). Indeed, important DNA methylation/demethylation maps have been shown to reflect
cell types and differentiation stages [42].

Figure 2 The link between DNA methylation, myeloid or the lymphoid lineage
commitment, self-renewal and differentiation – knowledge gained from mouse models.
(Note: Lymphoid/myeloid differentiation in the bone marrow compartment is tightly
regulated at the epigenetic level, with an observed increase in DNA methylation levels
following lymphoid commitment, predominating at myeloid transcription factor
binding sites, and a decrease as myeloid differentiation progresses.
DNMT1 inhibition in hematopoietic progenitors skews progenitors toward the myeloid
state, causing enhanced cell cycling of myeloid progenitor cells and reduced lymphoid
differentiation potential. Homozygous DNMT3A and DNMT3B deficiency at the
hematopoietic stem cell (HSC) stage of differentiation generates global DNA
demethylation associated with HSC multipotency, self-renewal gene upregulation and
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downregulation of differentiation factors, which results in a severe block in
myeloid/lymphoid differentiation and enhanced HSC self-renewal. Heterozygous
Dnmt3a null (Dnmt3a+/–) mice develop myeloid skewing over time and myeloid
malignancies after a long latent period.
TET1-deficient mice develop a lymphoproliferative disease at an advanced age
(approximately 2 years), with a mature germinal center B cell phenotype. TET2deficient mice present an altered cell differentiation with skewing toward
monocytic/granulocytic lineages observed and development of chronic
myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS) and acute
myeloid leukemia (AML). The B cell-specific TET2-knockout, on the other hand, leads to
abnormalities in the B1 cell subset and a development of B cell malignancies. The
combined loss of TET1/TET2 in HSC generates the development of lethal B cell
neoplasms whereas the dual loss of TET2/TET3 results in aggressive myeloid leukemia,
with an almost complete loss of 5-hmCyt.
IDH1-R132H knock-in mice shared similar phenotypes with the Tet2-knockout mice,
including global 5-hmCyt reduction, altered DNA methylation, impaired hematopoietic
differentiation, myeloid skewing and the development of myeloid disorders. IDH2R140Q transgenic mice showed normal HSC numbers and lineage differentiation, but
exhibited increased extramedullary hematopoiesis and, when combined with
HoxA9/Meis1 or FLT3 mutations in hematopoietic cells, produced acute myeloid
leukemia.)
Lymphoid/myeloid differentiation in the bone marrow compartment is tightly regulated at the
epigenetic level, with an observed increase in DNA methylation levels following lymphoid
commitment, and a decrease as myeloid differentiation progresses [43]. DNA methylation
mapping at the CpG level in the primitive hematopoietic compartment has revealed a progressive
and specific methylation accumulation during lymphoid differentiation that predominates at
myeloid transcription factor binding sites [42]. This suggests that DNA methylation is important for
cell fate determination and the balanced commitment to the myeloid or the lymphoid lineages.
Multiple transgenic mouse models have been established to study the role of epigenetics in the
hematopoietic lymphoid/myeloid differentiation process. The fact that DNA methylation profiling
of murine hematopoietic progenitors involves more global methylation enrichment during early
lymphopoiesis than during myelopoiesis could explain why DNMT1 inhibition skews progenitors
toward the myeloid state [43]. In other words, these data suggest that DNMT1 differentially
controls the myeloid and lymphoid lineages, causing enhanced cell cycling of myeloid progenitor
cells and reduced lymphoid differentiation potential [43].
Next, to determine whether constitutive methylation is continuously required throughout
lymphoid differentiation, DNMT1 was also inhibited in lymphoid progenitors. In contrast to the
previous mouse model, normal numbers and undisturbed homeostasis of B lymphoid cells were
detected. Therefore, once the B cell program is established, a lower sustained constitutive DNA
methylation is sufficient to maintain B cell identity and maturation [43].
Although it has been clearly shown that lymphoid commitment of the HSC is protected by
DNMT1 and involves a global increase in DNA methylation, the roles of DNMT3A and DNMT3B at
this early stage of B cell differentiation are less clear. DNMT3A-null HSCs exhibit global DNA
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demethylation but show both increased and decreased DNA methylation at different loci [44].
These modifications are associated with upregulation of HSC multipotency and self-renewal genes
as well as downregulation of differentiation factors. Serial transplantation of DNMT3A-null HSC
progressively impairs HSC differentiation [44]. Conditional loss of DNMT3B in HSC, another de
novo methyltransferase, results in minimal phenotypic effects; however, combined loss of
DNMT3B and DNMT3A results in a more severe block in myeloid/lymphoid differentiation and an
enhanced HSC self-renewal similar to that observed in DNMT3A-null HSCs [45] Together, these
data suggest a crucial role of de novo methyltransferases, particularly DNMT3A, in determining
HSC differentiation and self-renewal, their expression being required to allow HSC to differentiate
into the myeloid/lymphoid lineage.
Hematopoiesis was also evaluated in mice heterozygous for a constitutive Dnmt3a null
mutation. With no other manipulations, Dnmt3a+/– mice developed myeloid skewing over time
and their HSCs exhibited a long-term competitive transplantation advantage. Furthermore,
Dnmt3a+/– mice also spontaneously developed transplantable myeloid malignancies after a long
latent period [46].
Interestingly, in a different mouse model bearing a defective DNMT3a gene under control of
the immunoglobulin heavy chain enhancer (Eμ-DNMT3a-/-), DNMT3A inactivation occurred in
both embryonic and adult stem and progenitor hematopoietic cells. Moreover, mice did not
develop a myeloid disease but, in contrast, a lymphoproliferative disease resembling CLL or a
peripheral T cell lymphoma phenotype [47].
DNA hydroxymethylation enzymes also play important roles in HSC differentiation. In
transgenic TET1 knockout mice, HSC analysis showed global loss of 5-hmCyt with greater losses in
5-hmCyt occurring in gene bodies (exons and introns), important gains in 5-mCyt at promoters,
and increased self-renewal potential [48]. TET1-deficient mice further developed a
lymphoproliferative disease at an advanced age (approximately 2 years), with a mature germinal
center (GC) B cell phenotype [48]. In Tet2-deficient mice, an altered cell differentiation skewed
toward monocytic/granulocytic lineages was observed and Tet2-knockout mice develop chronic
myelomonocytic leukemia (CMML), MDS and AML with increased proliferation of the HSC
compartment [49]. It is important to note that the B cell-specific Tet2-knockout (CD19-TET2-/-), on
the other hand, leads to abnormalities in the B1 cell subset and a development of B cell
malignancies showing similarities to human CLL, including CD5 expression and sensitivity to
ibrutinib-mediated B cell receptor (BCR) signaling inhibition [50]. Interestingly, the combined loss
of Tet1/Tet2 in HSC is associated with the development of lethal B cell neoplasms, while the dual
loss of Tet2/Tet3 results in aggressive myeloid leukemia with an almost complete loss of 5-hmCyt
[51, 52].
Heterozygous mutations in the catalytic arginine residues of isocitrate dehydrogenases 1 and 2
(IDH1 and IDH2) are common in MDS and LAM and the mutant enzymes acquire a neomorphic
activity by converting the TET substrate α-ketoglutarate (α-KG) to D-2-hydroxyglutarate (2-HG).
The IDH1-R132H knock-in mice shared similar phenotypes with the Tet2 knockout mice, including
global 5-hmCyt reduction, altered DNA methylation, impaired hematopoietic differentiation,
myeloid skewing and the development of myeloid disorders [53].The IDH2-R140Q transgenic mice
showed normal HSC numbers and lineage differentiation, but exhibited increased extramedullary
hematopoiesis and, when combined with HoxA9/Meis1 or FLT3 mutations in hematopoietic cells,
produced acute leukemia [54].
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4. Alterations within Epigenetic Regulators in MDS/AML and CLL
4.1. DNMT1
DNMT1 is significantly overexpressed in AML [55, 56]. However, mutations of DNMT1 are rarely
observed in contrast to the frequent appearance of DNMT3A mutations in AML and MDS [57, 58]
(Table 1). DNMT1 forms complexes with important transcription factors with established roles in
AML, highlighting a possible pathoepigenetic interconnection in the disease biology. For example,
recent studies suggest that DNMT1 transcription is modulated by the Sp1 transcription factor [59].
The regulatory functions of Sp1 are mediated through its physical interaction with other
transcription factors, such as those of the NF-κB family that are constitutively activated in AML [59,
60]. Such interactions were shown to lead to increased DNMT1 expression and consequently, gene
silencing both in vivo and in vitro [59]. RUNX1, which is mutated in 20% of AML and MDS cases, is
a weak transcription activator although, its transcriptional potential is enhanced by acting in
synergy with lineage specific transcription factors. DNMT1 inhibition in RUNX1 AML restores
terminal differentiation through the switch of the RUNX1-Pu.1 coactivator/corepressor activity
complex via the interaction of Pu.1 with DNMT1 [61]. Minimally decreased expression of Pu.1 in
mice may induce a pre-leukemic state with dysplastic features and initiate AML [62].
An important feature of AML is the existence of characteristic fusion genes, which might confer
a worse (mixed lineage leukemia (MLL)-TET1/LCX fusions) or better (PML-RARα) prognosis. The
PML-RARα onco-fusion induces hypermethylation by recruiting DNMT1 and DNMT3A in target
promoters, such as RARb2, and is also required for the normal localization of DNMT1, which is
otherwise dispersed in the nucleus [63]. Similarly, through its physical association with DNMT1,
the AML-ETO fusion binds and hypermethylates AML target gene promoters [64]. DNMT1 is
indirectly regulated via the miR-29b-Sp1 complex, which binds physically to the DNMT1 promoter
to positively regulate its expression. Hence, there is a miR-29b-Sp1-DNMT1 axis in AML that is
deregulated beginning with the underexpression of miR-29b. Forced miR-29b expression leads to
restored expression of DNMT1 and its target genes p15 and ESR1, inducing partial differentiation
of blast cells [65, 66].
However, the role of the miR-29 family in epigenetic regulation is much more complex, because
not only DNMT3A, DNMT3B, but also TET1 and thymine DNA glycosidase (TDG) are direct targets
of miR-29. Furthermore, miR-29 overexpression has been shown to upregulate the global DNA
methylation level in some cancer cells and downregulate DNA methylation in others [67, 68].
In comparisons of DNMT1 expression in CLL with normal CD19+ B cells and memory B cells, no
differences were observed [12, 69]. In addition, we have previously published data demonstrating
an absence of significant differences between the IGHV-UM and IGHV-M CLLs and stable
expression of DNMT1 during disease progression, which further supports a minor role for DNMT1
in disease progression [12].
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Table 1 Epigenetic regulators in myelodisplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
Functions Genes

MDS
(mutation
frequency %)

Effect of mutations
on transcription
(gain/loss of
function)
NR

AML
(mutation
frequency %)

Effect of mutations on
transcription
(gain/loss of function)

CLL (mutation
frequency %)

Rare [58]

NR

NR

Effect of mutations
on transcription
(gain/loss of
function)
NR

DNMT1
DNA
methylati DNMT3A
on

4.7 [70]
7.9 [71]

activation (loss of
function)

22.1 [72]

activation (loss of
function)

NR

NR

TET1

NR

NR

rare [73]

NR

2.8 [74]

NR

TET2

18.3 [75]

NR (loss of
function)

12 [73]

ND (loss of function)

2.3 [74]

NR

NR

NR

rare [73]

NR

3.2 [74]

NR

2.8 [70]

NR (gain of
function)

8.9 [76]

NR (gain of function)

2.3 [74]

NR

0.9 [70]

NR (gain of
function)

10.4 [77]

NR (gain of function)

0.9 [74]

NR

DNA
TET3
hydroxy
methylati
IDH1
on
IDH2

DNMT, DNA methyltransferase; TET, ten-eleven translocation; IDH, isocytrate dehydrogenase; NR, not reported.
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4.2. DNMT3A
DNMT3A can be mutated in both MDS and AML. DNMT3A mutations, which occur in less than
10% of MDS cases and 12%–35% of AML, are most commonly heterozygous. DNMT3A R882(C/H)
represents the most frequent mutation and is associated with poorer survival [65, 78, 79].
DNMT3A R882H mutants show both decreased methyltransferase activity and dominant negative
functions as its overexpression results in hypomethylation [80, 81]. Therefore, a partial, rather
than complete inactivation of DNMT3A is likely more relevant in the pathogenesis of AML/MDS.
Although they occur less frequently in MDS, DNMT3A mutations may represent a risk factor for
progression to AML [82]. Furthermore, several studies have provided evidence that DNMT3A
mutations represent early events in leukemogenesis, and may also be present in T lymphocytes
derived from AML patients. This observation shows that DNMT3A mutations are harbored within
founding clones that retain the capacity to give rise to both myeloid and lymphoid lineages [83-85];
DNMT3A mutations are also thought to occur early in MDS [78].
However, acquired DNMT3A mutations are highly prevalent in age-associated clonal
hematopoiesis in normal individuals with low or no biological impact and an, as yet, undefined
oncogenic risk [86]. This suggests that mutations in epigenetic modifiers, such as DNMT3A, are
permissive for leukemogenesis but not sufficient to initiate transformation alone.
The effect of DNMT3A mutations on DNA methylation in AML is controversial, possibly due to
the different technical platforms used by various investigators. By using liquid chromatography
tandem mass spectrometry or ELISA-based DNA methylation measurements to identify global
changes in 5-mCyt, no statistical difference was detected in bulk 5-mCyt [72, 87]. However, by
using HM-450K BeadChip arrays and separating DNMT3A wild-type, DNMT3A R882-mutant, and
DNMT3A non-R882-mutant AMLs, the R882 mutant AMLs were found to have lower mean
methylation values than were detected in both the non-R882 and DNMT3A wild-type patients [81].
Hypomethylation is rather more focal than global and mainly localized in CpG islands and shores.
In CLL, several studies, including our own recently published report, have shown DNMT3A
downregulation during disease progression, compared to normal CD19+ B cells or memory B cells
[12, 69, 88]. Indeed, DNMT3A transcript levels decrease in CLL patients who progress from the
indolent Binet A stage to the more aggressive Binet B/C stages [12]. On the other hand, in patients
with stable disease (Binet A) for more than 5 years, there was no significant difference in the
DNMT3A levels between the two time points [12]. Thus, it is unsurprising that low DNMT3A levels
are associated with negative prognostic impact cytogenetic anomalies, such as 17p deletion,
trisomy 12 or a complex karyotype and with a shorter treatment-free survival (TFS) [12, 89]. Our
group also evaluated the association of DNMT3A downregulation in the progressive CLL disease
group with changes in 5-mCyt levels by using the base resolution sequencing technique, RRBS,
which revealed a significant decrease in DNA 5-mCyt in all regions of the genome (unpublished
data). These findings support the view that loss in DNMT3A activity represents a driver for
MDS/AML progression, and a risk factor for disease activity in CLL as reported previously in the
DNMT3a+/- and Eμ-DNMT3a-/- mice, respectively.
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4.3. TET1
TET1 was first identified as a fusion partner, TET1/LCX, of the MLL gene in AML carrying
t(10,11)(q22;q23). Furthermore, TET1 represents a direct target of MLL-fusion proteins, such as
HOXA9, MEIS1, and PBX3, and is significantly upregulated in MLL-rearranged leukemia, leading to
a global increase in 5-hmCyt levels [90]. In normal cytogenetic AML, TET1 overexpression is
associated with poor survival [91].
In CLL, somatic mutations in the TET1 gene represent rare events (2.8%) and CLL B cells have
similar transcriptional levels of TET1 to those observed in control memory B cells [12, 74].
However, low levels of TET1 are associated with shorter TFS [12].
4.4. TET2
TET2 is mutated in approximately 12%–20% of AMLs, 23%–35% of MDS and 50% of CMML [92,
93]. These loss-of-function mutations are diverse and impair TET2 activity [93, 94]. In primary MDS
and AML patients harboring TET2 mutations, significantly reduced global 5-hmCyt levels have
been revealed [87, 95].
However, TET2 mutations, like those present in DNMT3A, are frequent in age-associated clonal
hematopoiesis in normal individuals with low or no biological impact, which shows these
mutations are not sufficient to initiate leukemogenesis alone [86].
In CLL, only 3.2% of patients present somatic mutations in TET2. In the early stage of the
disease TET2 transcript levels in CLL are similar to those of control memory B cells, while
important variations in TET2 levels are reported between CLL patients [12, 73]. In these two
reports, a reduction in TET2 is associated with a lower median TFS, supporting an unexpected role
for TET2 as an oncogenic repressor.
4.5. Isocitrate Dehydrogenase-1 (IDH1) and -2 (IDH2)
The isocitrate dehydrogenase-1 (IDH1) and -2 (IDH2) genes encode NADP+ dependent enzymes
that convert isocitrate to -KT in the Krebs cycle. IDH1 functions in the cytoplasm whereas IDH2 is
localized to the mitochondria. Mutations in the genes encoding IDH1 and IDH2 tend not to occur
together in the same clone and have been described in 15%–30% of AMLs [96]. Mutations result in
a new enzymatic function resulting in the aberrantly accelerated conversion of -KG to 2-HG [97].
The accumulation of the metabolite 2-HG has been shown to be responsible for the inhibition of
TET2 function, thus ultimately inhibiting hydroxymethylation of DNA. Mutations in IDH1/2 and
TET2 mutations are mutually exclusive in AML and, as expected, patients show similar DNA
methylation profiles [98]. While the prognostic impact of IDH mutations in AML is controversial
and remains unclear, clinical trials using inhibitors that are relatively specific for IDH1 and IDH2 are
ongoing [99-101].
In CLL, IDH1/2 mutations are extremely rare (0.9%) and decreased expression of IDH2 in
addition to IDH1 overexpression were revealed in CLL B cells compared to the levels detected in
normal CD19+ B cells [74].
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5. Conclusions
Advances in gene expression profiling and the development of new and improved highthroughput techniques for exploring methylation and hydroxymethylation of DNA have provided a
more accurate and detailed understanding of the genetic and epigenetic basis for the
development of hematopoietic diseases. Since their discovery, many important advances have
also been made in our mechanistic understanding of the enzymes implicated in DNA methylation
and demethylation processes.
However, although these enzymatic processes have been thoroughly characterized and highresolution co-crystal structures of human DNMTs and TETs and their substrates have provided
structural insights into their activities, several fundamental aspects of these processes and their
implications in hematologic myeloid and lymphoid malignancies remain to be fully elucidated. First,
concurrent recruitment of auxiliary factors by DNMT and TET proteins to genomic target sites is
far from clear at the moment. Although several interactions have been demonstrated, studying
these interactions in association with specific oncogenes or tumor suppressor genes implicated in
hematologic malignancies could provide important information concerning their roles in these
pathologies.
Second, the mechanisms that govern recruitment and localization of DNMTs and TETs to DNA
are not fully understood. Addressing these questions will be an important part of future
investigations.
We chose to discuss epigenetic modifications from two perspectives – the myeloid lineage
pathologies, MDS/AML, in which epigenetic regulators are dysregulated because they present
somatic mutations, and the lymphoid lineage pathology, CLL, in which epigenetic regulators are
rarely mutated, but are highly dysregulated (Figure 3). With regard to MDS/AML, epigenetic
dysregulation is an early event in the development of HSC. In CLL, on the other hand, there is a
step-wise process of leukemogenesis and disease progression, and epigenetic regulators and
methylation have an important dynamic correlation with disease progression and prognosis.
Irrespective of the underlying molecular events, DNMT3A and TET2 in particular are
dysregulated in MDS/AML and CLL, leading to altered DNA methylation and hydroxymethylation
pattern. Advances in gene expression profiling and the development of new and improved highthroughput techniques for exploring methylation and hydroxymethylation of DNA have provided a
more accurate and detailed understanding of the genetic and epigenetic basis for the
development of hematopoietic diseases. Since their discovery, many important advances have
also been made in our mechanistic understanding of the enzymes implicated in DNA methylation
and demethylation processes.
However, although these enzymatic processes have been thoroughly characterized and highresolution co-crystal structures of human DNMTs and TETs and their substrates have provided
structural insights into their activities, several fundamental aspects of these processes and their
implications in hematologic myeloid and lymphoid malignancies remain to be fully elucidated. First,
concurrent recruitment of auxiliary factors by DNMT and TET proteins to genomic target sites is
far from clear at the moment. Although several interactions have been demonstrated, studying
these interactions in association with specific oncogenes or tumor suppressor genes implicated in
hematologic malignancies could provide important information concerning their roles in these
pathologies.
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Second, the mechanisms that govern recruitment and localization of DNMTs and TETs to DNA
are not fully understood. Addressing these questions will be an important part of future
investigations.
We chose to discuss epigenetic modifications from two perspectives – the myeloid lineage
pathologies, MDS/AML, in which epigenetic regulators are dysregulated because they present
somatic mutations, and the lymphoid lineage pathology, CLL, in which epigenetic regulators are
rarely mutated, but are highly dysregulated (Figure 3). With regard to MDS/AML, epigenetic
dysregulation is an early event in the development of HSC. In CLL, on the other hand, there is a
step-wise process of leukemogenesis and disease progression, and epigenetic regulators and
methylation have an important dynamic correlation with disease progression and prognosis.
Irrespective of the underlying molecular events, DNMT3A and TET2 in particular are
dysregulated in MDS/AML and CLL, leading to altered DNA methylation and hydroxymethylation
patterns that confer a competitive advantage to the myeloid or lymphoid lineage and an
imbalance between self-renewal and differentiation. A better understanding of their localization
and their co-recruitment of other proteins at specific DNA target sites could provide us with the
possibility to modulate hematopoiesis, restore the initial balance, and control disease
progressions that confer a competitive advantage to the myeloid or lymphoid lineage and an
imbalance between self-renewal and differentiation. A better understanding of their localization
and their co-recruitment of other proteins at specific DNA target sites could provide us with the
possibility to modulate hematopoiesis, restore the initial balance, and control disease progression.

Figure 3 Epigenetic dysregulation in myelodysplastic syndrome (MDS)/acute myeloid
leukemia (AML) and in chronic lymphocytic leukemia (CLL).
(Note: In MDS and AML, epigenetic dysregulation is an early event caused by somatic
mutations in hematopoietic stem cells, which generate a loss of function at the protein
level and a poor prognosis. In CLL, epigenetic regulators are rarely mutated, but highly
dysregulated, with their expression diminishing in association with disease
progression.)

Page 14/21

OBM Genetics 2018; 2(4), doi:10.21926/obm.genet.1804054

Acknowledgments
Authors express their gratitude to Simone Forest and Geneviève Michel for their help in editing
the paper. This study was supported by research funding from the “Association Laurette Fugain”
(ALF 2015/03), the “ligue against the cancer sections 29/35/49, the "Region Bretagne" and from
the REpiCGO an Epigenetic network of the "Cancéropole Grand Ouest".
Author Contributions
The original manuscript was written by CBa and YR (main expertise in epigenetics/CLL) and the
other authors (main expertise in MDS/AML and/or epigenetics) modified and approved the final
manuscript.
Competing Interests
The authors have declared that no competing interests exist.
References
1.

Shallis RM, Ahmad R, Zeidan AM. The genetic and molecular pathogenesis of myelodysplastic
syndromes. Eur J Haematol. 2018; 101: 260-271.
2. Gilliland DG, Tallman MS. Focus on acute leukemias. Cancer Cell. 2002; 1: 417-420.
3. Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient
survival among children and adults in the United States, 2001-2007. Blood. 2012;119: 34-43.
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. "Cancer statistics, 2007. CA Cancer J Clin.
2007; 57: 43-66.
5. Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and
treatment. Am J Hematol. 2017; 92: 946-965.
6. Renadineau Y, Bariller E, Pers JO. B1‐ and CD5‐ Positive B Cells. eLS. 2014; DOI:
10.1002/9780470015902.a0024242.
7. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression
profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to
memory B cells. J Exp Med. 2001; 194: 1625-1638.
8. Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, et al. DNA methylation
dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic
lymphocytic leukemia. Nat Genet. 2016; 48: 253-264.
9. Kikushige Y, Ishikawa F, Miyamoto T, Shima T, Urata S, Yoshimoto G, et al. Self-renewing
hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic
leukemia. Cancer Cell. 2011; 20: 246-259.
10. Garaud S, Le Dantec C, Berthou C, Lydyard PM, Youinou P, Renaudineau Y. Selection of the
alternative exon 1 from the cd5 gene down-regulates membrane level of the protein in B
lymphocytes. J Immunol. 2008; 181: 2010-2018.
11. Mankai A, Bordron A, Renaudineau Y, Martins-Carvalho C, Takahashi S, Ghedira I, et al.
Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of
chronic lymphocytic leukemia B cells. Cancer Res. 2008; 68: 7512-7519.

Page 15/21

OBM Genetics 2018; 2(4), doi:10.21926/obm.genet.1804054

12. Bagacean C, Tempescul A, Le Dantec C, Bordron A, Mohr A, Saad H, et al. Alterations in DNA
methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic
leukemia. Oncotarget. 2017; 8: 65699-65716.
13. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje
neurons and the brain. Science. 2009; 324: 929-930.
14. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science.
2009; 324: 930-935.
15. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, et al. Human DNA
methylomes at base resolution show widespread epigenomic differences. Nature. 2009; 462:
315-322.
16. Renaudineau Y, Hillion S, Saraux A, Mageed RA, Youinou P. An alternative exon 1 of the CD5
gene regulates CD5 expression in human B lymphocytes. Blood. 2005; 106: 2781-2789.
17. Renaudineau Y, Vallet S, Le Dantec C, Hillion S, Saraux A, Youinou P. Characterization of the
human CD5 endogenous retrovirus-E in B lymphocytes. Genes Immun. 2005; 6: 663-671.
18. Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet.
2013; 14: 204-220.
19. Le Dantec C, Vallet S, Brooks WH, Renaudineau Y. Human endogenous retrovirus group E and
its involvement in diseases. Viruses. 2015; 7: 1238-1257.
20. Brenet F, Moh M, Funk P, Feierstein E, Viale AJ, Socci ND, et al. DNA methylation of the first
exon is tightly linked to transcriptional silencing. PLoS One. 2011; 6: e14524.
21. Brooks WH, Renaudineau Y. Epigenetics and autoimmune diseases: the X chromosomenucleolus nexus. Front Genet. 2015; 6: 22.
22. Charras A, Konsta OD, Le Dantec C, Bagacean C, Kapsogeorgou EK, Tzioufas AG, et al. Cellspecific epigenome-wide DNA methylation profile in long-term cultured minor salivary gland
epithelial cells from patients with Sjogren's syndrome. Ann Rheum Dis. 2017; 76: 625-628.
23. Madakashira BP, Sadler KC. DNA Methylation, Nuclear Organization, and Cancer. Front Genet.
2017; 8: 76.
24. Brandeis M, Frank D, Keshet I, Siegfried Z, Mendelsohn M, Nemes A, et al. Sp1 elements
protect a CpG island from de novo methylation. Nature. 1994; 371: 435-438.
25. Macleod D, Charlton J, Mullins J, Bird AP. Sp1 sites in the mouse aprt gene promoter are
required to prevent methylation of the CpG island. Genes Dev. 1994; 8: 2282-2292.
26. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene. 2001; 20: 31393155.
27. Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y. Epigenetics and autoimmunity. J
Autoimmun. 2010; 34: J207-219.
28. Bestor TH, Ingram VM. Two DNA methyltransferases from murine erythroleukemia cells:
purification, sequence specificity, and mode of interaction with DNA. Proc Natl Acad Sci USA.
1983; 80: 5559-5563.
29. Bestor TH. Cloning of a mammalian DNA methyltransferase. Gene. 1988; 74: 9-12.
30. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA
(cytosine-5) methyltransferases. Nat Genet. 1998; 19: 219-220.

Page 16/21

OBM Genetics 2018; 2(4), doi:10.21926/obm.genet.1804054

31. Deplus R, Brenner C, Burgers WA, Putmans P, Kouzarides T, de Launoit Y, et al. Dnmt3L is a
transcriptional repressor that recruits histone deacetylase. Nucleic Acids Res. 2002; 30: 38313838.
32. Wyatt GR, Cohen SS. A new pyrimidine base from bacteriophage nucleic acids. Nature. 1952;
170: 1072-1073.
33. Rasmussen KD, Helin K. Role of TET enzymes in DNA methylation, development, and cancer.
Genes Dev. 2016; 30: 733-750.
34. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. Tet proteins can convert 5methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011; 333: 1300-1303.
35. Bagacean C, Zdrenghea M, Dantec CL, Tempescul A, Berthou C, Renaudineau Y. DNA
demethylation marks in chronic lymphocytic leukemia: it is time to let the cat out of the bag.
Future Sci OA. 2018; 4: FSO265.
36. Nestor CE, Ottaviano R, Reddington J, Sproul D, Reinhardt D, Dunican D, et al. Tissue type is a
major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res. 2012;
22: 467-477.
37. Zhang X, Su J, Jeong M, Ko M, Huang Y, Park HJ, et al. DNMT3A and TET2 compete and
cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat
Genet. 2016; 48: 1014-1023.
38. Huang Y, Chavez L, Chang X, Wang X, Pastor WA, Kang J, et al. Distinct roles of the
methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells. Proc Natl Acad Sci
USA. 2014; 111: 1361-1366.
39. Gu T, Lin X, Cullen SM, Luo M, Jeong M, Estecio M, et al. DNMT3A and TET1 cooperate to
regulate promoter epigenetic landscapes in mouse embryonic stem cells. Genome Biol. 2018;
19: 88.
40. Deplus R, Delatte B, Schwinn MK, Defrance M, Mendez J, Murphy N, et al. TET2 and TET3
regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J.
2013; 32: 645-655.
41. Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, Rappsilber J, et al. TET1 and
hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature. 2011; 473: 343348.
42. Bock C, Beerman I, Lien WH, Smith ZD, Gu H, Boyle P, et al. DNA methylation dynamics during
in vivo differentiation of blood and skin stem cells. Mol Cell. 2012; 47: 633-647.
43. Ji H, Ehrlich LI, Seita J, Murakami P, Doi A, Lindau P, et al. Comprehensive methylome map of
lineage commitment from haematopoietic progenitors. Nature. 2010; 467: 338-342.
44. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, et al. Dnmt3a is essential for
hematopoietic stem cell differentiation. Nat Genet. 2011; 44: 23-31.
45. Challen GA, Sun D, Mayle A, Jeong M, Luo M, Rodriguez B, et al. Dnmt3a and Dnmt3b have
overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell. 2014; 15: 350364.
46. Cole CB, Russler-Germain DA, Ketkar S, Verdoni AM, Smith AM, Bangert CV, et al.
Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid
malignancies. J Clin Invest. 2017; 127: 3657-3674.

Page 17/21

OBM Genetics 2018; 2(4), doi:10.21926/obm.genet.1804054

47. Peters SL, Hlady RA, Opavska J, Klinkebiel D, Pirruccello SJ, Talmon GA, et al. Tumor
suppressor functions of Dnmt3a and Dnmt3b in the prevention of malignant mouse
lymphopoiesis. Leukemia. 2014; 28: 1138-1142.
48. Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, et al. TET1 is a tumor
suppressor of hematopoietic malignancy. Nat Immunol. 2015; 16: 653-662.
49. Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE, et al. Deletion of Tet2 in mice leads to
dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.
Blood. 2011; 118: 4509-4518.
50. Mouly E, Ghamlouch H, Della-Valle V, Scourzic L, Quivoron C, Roos-Weil D, et al. B-cell tumor
development in Tet2-deficient mice. Blood Adv. 2018; 2: 703-714.
51. An J, Gonzalez-Avalos E, Chawla A, Jeong M, Lopez-Moyado IF, Li W, et al. Acute loss of TET
function results in aggressive myeloid cancer in mice. Nat Commun. 2015; 6: 10071.
52. Zhao Z, Chen L, Dawlaty MM, Pan F, Weeks O, Zhou Y, et al. Combined Loss of Tet1 and Tet2
Promotes B Cell, but Not Myeloid Malignancies, in Mice. Cell Rep. 2015; 13: 1692-1704.
53. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models,
and clinical opportunities. Cancer Discov. 2013; 3: 730-741.
54. Kats LM, Reschke M, Taulli R, Pozdnyakova O, Burgess K, Bhargava P, et al. Proto-oncogenic
role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell. 2014; 14: 329-341.
55. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, et al. Expression of DNA
methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic
myelogenous leukemia. Blood. 2001; 97: 1172-1179.
56. Langer F, Dingemann J, Kreipe H, Lehmann U. Up-regulation of DNA methyltransferases
DNMT1, 3A, and 3B in myelodysplastic syndrome. Leuk Res. 2005; 29: 325-329.
57. Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S,
Haldemann B, et al. Commonly altered genomic regions in acute myeloid leukemia are
enriched for somatic mutations involved in chromatin remodeling and splicing. Blood. 2012;
120: e83-92.
58. Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al.
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med.
2013; 368: 2059-2074.
59. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, et al. Bortezomib induces DNA hypomethylation
and silenced gene transcription by interfering with Sp1/ NF-kappaB-dependent DNA
methyltransferase activity in acute myeloid leukemia. Blood. 2008; 111: 2364-2373.
60. Perkins ND, Edwards NL, Duckett CS, Agranoff AB, Schmid RM, Nabel GJ. A cooperative
interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J.
1993; 12: 3551-3558.
61. Gu X, Hu Z, Ebrahem Q, Crabb JS, Mahfouz RZ, Radivoyevitch T, et al. Runx1 regulation of Pu.1
corepressor/coactivator exchange identifies specific molecular targets for leukemia
differentiation therapy. J Biol Chem. 2014; 289: 14881-14895.
62. Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, da Silva Ferreira M, et al. Minimal
PU.1 reduction induces a preleukemic state and promotes development of acute myeloid
leukemia. Nat Med. 2015; 21: 1172-1181.

Page 18/21

OBM Genetics 2018; 2(4), doi:10.21926/obm.genet.1804054

63. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, et al. Methyltransferase
recruitment and DNA hypermethylation of target promoters by an oncogenic transcription
factor. Science. 2002; 295: 1079-1082.
64. Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ, Ford JL, et al. Interplay of RUNX1/MTG8 and DNA
methyltransferase 1 in acute myeloid leukemia. Cancer Res. 2005; 65: 1277-1284.
65. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, et al. MicroRNA-29b induces global
DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by
targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009; 113: 6411-6418.
66. Bernot KM, Nemer JS, Santhanam R, Liu S, Zorko NA, Whitman SP, et al. Eradicating acute
myeloid leukemia in a Mll(PTD/wt): Flt3(ITD/wt) murine model: a path to novel therapeutic
approaches for human disease. Blood.2013; 122: 3778-3783.
67. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts
aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B." Proc
Natl Acad Sci USA. 2007; 104: 15805-15810.
68. Morita S, Horii T, Kimura M, Ochiya T, Tajima S, Hatada I. MiR-29 represses the activities of
DNA methyltransferases and DNA demethylases. Int J Mol Sci. 2013; 14: 14647-14658.
69. Kn H, Bassal S, Tikellis C, El-Osta A. Expression analysis of the epigenetic methyltransferases
and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic
leukemia (CLL). Cancer Biol Ther. 2004; 3: 989-994.
70. Jung SH, Kim YJ, Yim SH, Kim HJ, Kwon YR, Hur EH, et al. Somatic mutations predict outcomes
of hypomethylating therapy in patients with myelodysplastic syndrome. Oncotarget. 2016; 7:
55264-55275.
71. Lin ME, Hou HA, Tsai CH, Wu SJ, Kuo YY, Tseng MH, et al. Dynamics of DNMT3A mutation and
prognostic relevance in patients with primary myelodysplastic syndrome. Clin Epigenetics.
2018; 10: 42.
72. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in
acute myeloid leukemia. N Engl J Med. 2010; 363: 2424-2433.
73. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, et al. Genetic
characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;
114: 144-147.
74. Van Damme M, Crompot E, Meuleman N, Maerevoet M, Mineur P, Bron D, et al.
Characterization of TET and IDH gene expression in chronic lymphocytic leukemia:
comparison with normal B cells and prognostic significance. Clin Epigenetics. 2016; 8: 132.
75. Guo Z, Zhang SK, Zou Z, Fan RH, Lyu XD. Prognostic significance of TET2 mutations in
myelodysplastic syndromes: A meta-analysis. Leuk Res. 2017; 58: 102-107.
76. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations
found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361: 10581066.
77. Chotirat S, Thongnoppakhun W, Promsuwicha O, Boonthimat C, Auewarakul CU. Molecular
alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and
additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J Hematol
Oncol. 2012; 5: 5.
78. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, et al. Recurrent DNMT3A mutations
in patients with myelodysplastic syndromes. Leukemia. 2011; 25: 1153-1158.
Page 19/21

OBM Genetics 2018; 2(4), doi:10.21926/obm.genet.1804054

79. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, et al. Exome sequencing identifies somatic
mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet.
2011; 43: 309-315.
80. Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T. A DNMT3A mutation common in
AML exhibits dominant-negative effects in murine ES cells. Blood. 2013; 122: 4086-4089.
81. Russler-Germain DA, Spencer DH, Young MA, Lamprecht TL, Miller CA, Fulton R, et al. The
R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by
blocking its ability to form active tetramers. Cancer Cell. 2014; 25: 442-454.
82. Thol F, Winschel C, Ludeking A, Yun H, Friesen I, Damm F, et al. Rare occurrence of DNMT3A
mutations in myelodysplastic syndromes. Haematologica. 2011; 96: 1870-1873.
83. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed
acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481: 506-510.
84. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic
mutations in human acute myeloid leukemia affect epigenetic regulators and persist in
remission. Proc Natl Acad Sci USA. 2014; 111: 2548-2553.
85. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of preleukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014; 506: 328-333.
86. Buscarlet M, Provost S, Zada YF, Barhdadi A, Bourgoin V, Lepine G, et al. DNMT3A and TET2
dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic
predispositions. Blood. 2017; 130: 753-762.
87. Kroeze LI, Aslanyan MG, van Rooij A, Koorenhof-Scheele TN, Massop M, Carell T, et al.
Characterization of acute myeloid leukemia based on levels of global hydroxymethylation.
Blood. 2014; 124: 1110-1118.
88. Wang J, Morrissette J, Lieberman DB, Timlin C, Schuster SJ, Mato AR. Utilization of next
generation sequencing identifies potentially actionable mutations in chronic lymphocytic
leukaemia. Br J Haematol. 2018; 180: 299-301.
89. Bagacean C, Le Dantec C, Berthou C, Tempescul A, Saad H, Bordron A, et al. Combining
cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis
prediction for patients with isolated 13q deletion. Clin Epigenetics. 2017; 9: DOI:
10.1186/s13148-017-0422-7.
90. Huang H, Jiang X, Li Z, Li Y, Song CX, He C, et al. TET1 plays an essential oncogenic role in MLLrearranged leukemia. Proc Natl Acad Sci USA. 2013; 110: 11994-11999.
91. Wang J, Li F, Ma Z, Yu M, Guo Q, Huang J, et al. High Expression of TET1 Predicts Poor Survival
in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. EBioMedicine. 2018;
28: 90-96.
92. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance
of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366: 1079-1089.
93. Meldi KM, Figueroa ME. Cytosine modifications in myeloid malignancies. Pharmacol Ther.
2015; 152: 42-53.
94. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. Mutation in TET2
in myeloid cancers. N Engl J Med. 2009; 360: 2289-2301.
95. Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J, et al. DNA
hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in
acute myeloid leukemia. Cell Rep. 2014; 9: 1841-1855.
Page 20/21

OBM Genetics 2018; 2(4), doi:10.21926/obm.genet.1804054

96. Ohgami RS, Arber DA. The diagnostic and clinical impact of genetics and epigenetics in acute
myeloid leukemia. Int J Lab Hematol. 2015; 37: 122-132.
97. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature
of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting
alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17: 225-234.
98. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2
mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair
hematopoietic differentiation. Cancer Cell. 2010; 18: 553-567.
99. Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, et al. Prognostic impact
of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a
study by the Acute Leukemia French Association group. J Clin Oncol. 2010; 28: 3717-3723.
100. Koszarska M, Bors A, Feczko A, Meggyesi N, Batai A, Csomor J, et al. Type and location of
isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of
acute myeloid leukemia. Leuk Lymphoma. 2013; 54: 1028-1035.
101. Gallipoli P, Giotopoulos G, Huntly BJ. Epigenetic regulators as promising therapeutic targets in
acute myeloid leukemia. Ther Adv Hematol. 2015; 6: 103-119.

Enjoy OBM Genetics by:
1.
2.
3.
4.

OBM Genetics

Submitting a manuscript
Joining in volunteer reviewer bank
Joining Editorial Board
Guest editing a special issue

For more details, please visit:
http://www.lidsen.com/journals/genetics

Page 21/21

